Bioseeker, Feb 2011
projects in cancer. In addition, there are 2 (10) suspended drugs and the accumulated number of ceased drugs over the last years amount to another 79 (69) drugs. LymphomaDrugPipelineUpdate lists all drugs
Bioseeker, May 2011 PipelineUpdate 2011’*. The Package Includes: - A progress analysis on current and emerging drugs - Information on most companies active in lymphoma R&D - Information on key industry related lymphoma
Life Science Analytics, March 2011, Pages: 737
Non-Hodgkin Lymphoma Therapy Area Pipeline Report contains detailed information on the non-hodgkin lymphomadrugpipeline. This report provides insight into the pipeline status of non-hodgkin
Life Science Analytics, March 2011, Pages: 275
Lymphoma Therapy Area Pipeline Report contains detailed information on the lymphomadrugpipeline. This report provides insight into the pipeline status of lymphomadrugs by company and by stage
Life Science Analytics, March 2011, Pages: 108
Cutaneous T-cell Lymphoma Therapy Area Pipeline Report contains detailed information on the cutaneous t-cell lymphomadrugpipeline. This report provides insight into the pipeline status
Life Science Analytics, March 2011, Pages: 176
Hodgkin Lymphoma Therapy Area Pipeline Report contains detailed information on the hodgkin lymphomadrugpipeline. This report provides insight into the pipeline status of hodgkin lymphomadrugs
Global Markets Direct, Jan 2012, Pages: 61
Cell Lymphomas therapeutic pipeline. This report provides information on the therapeutic development for Natural Killer Cell Lymphomas, complete with latest updates, and special features on late-stage
Global Markets Direct, Jan 2012, Pages: 90
therapeutic pipeline. This report provides information on the therapeutic development for AIDS - Related Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects
Global Markets Direct, Jan 2012, Pages: 509
Profile
Revlimid + Rituxan - Drug Profile
Biosimilar Rituximab - Drug Profile
PBO-326 - Drug Profile
RO5072759 + Chemotherapy - Drug Profile
Lymphoma Therapeutics – Drug Profile Updates
Global Markets Direct, Dec 2010, Pages: 28
and major milestones.
- Recent updates of the German Low Grade Lymphoma Study Group’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products
Global Markets Direct, Dec 2010, Pages: 28
and major milestones.
- Recent updates of the Scotland and Newcastle Lymphoma Group’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products
Global Markets Direct, Jan 2012, Pages: 292
pipeline. This report provides information on the therapeutic development for Follicular Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews
Global Markets Direct, Dec 2010, Pages: 47
therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma , complete with latest updates, and special features on late-stage and discontinued projects
Global Markets Direct, July 2011, Pages: 59
Cell Lymphomas therapeutic pipeline. This report provides information on the therapeutic development for Natural Killer Cell Lymphomas, complete with latest updates, and special features on late-stage
